FDA reviewers demanded more data on Motavizumab, used to prevent respiratory syncytial virus (RSV) infections, before allowing it on the market. RSV is the major cause of lower respiratory tract infection during infancy and childhood. AstraZeneca PLC intended to launch Motavizumab in the second half of next year.